Circulating proinflammatory cytokines (IL-1β, TNF-α, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis
- 1 October 1994
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 98 (1) , 71-77
- https://doi.org/10.1111/j.1365-2249.1994.tb06609.x
Abstract
Fulminant hepatic failure (FHF) is characterized by massive necroinflammation of the liver tissue and is associated with high mortality. Serum concentrations of IL-1 beta, tumour necrosis factor-alpha (TNF-alpha), IL-6 and IL-1 receptor antagonist (IL-1Ra) were measured in 30 patients with FHF and in 23 patients with acute hepatitis (AH) before start of treatment and in 23 healthy controls. Levels of all four molecules were increased significantly in FHF compared with AH, in which values were higher than in the healthy controls. High serum levels of IL-1 beta and a significantly reduced ratio of IL-1Ra to IL-1 beta (IL-1Ra/IL-1 beta) were observed in FHF patients who subsequently died compared with subjects who survived. TNF-alpha and IL-6 concentrations were correlated with levels of human hepatocyte growth factor (hHGF), an index of hepatocyte regeneration. Although serum cytokine levels varied considerably between patients within each group studied, it is suggested that the striking elevation in proinflammatory cytokine levels in FHF may reflect both the insufficiency of hepatitis virus elimination and a failure to control a vicious cytokine cascade leading to overwhelming hepatocyte destruction rather than regeneration. The high cytokine levels observed in these patients and the significantly elevated IL-1Ra/IL-1 beta ratio in FHF patients who survived compared with those who did not suggest the possible therapeutic use of cytokine antagonists for the control of this life-threatening disease.Keywords
This publication has 46 references indexed in Scilit:
- Circulating interleukin-1 and tumor necrosis factor antagonists in liver diseaseHepatology, 1993
- Development of reliable artificial liver support (ALS)-plasma exchange in combination with hemodiafiltration using high-performance membranesDigestive Diseases and Sciences, 1993
- Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitroImmunology Today, 1991
- Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infectionPublished by Elsevier ,1991
- ENHANCED TUMOUR NECROSIS FACTOR AND INTERLEUKIN-1 IN FULMINANT HEPATIC FAILUREThe Lancet, 1988
- Tumor necrosis factor stimulates DNA synthesis in the liver of intact ratsBiochemical and Biophysical Research Communications, 1988
- Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro.The Journal of cell biology, 1986
- Induction of β2-interferon by tumor necrosis factor: A homeostatic mechanism in the control of cell proliferationCell, 1986
- Fulminant Hepatitis: Mayo Clinic Experience With 34 CasesMayo Clinic Proceedings, 1985
- Homogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1Nature, 1985